Cardiac Rhythm Management Devices Patent Landscape
This field is heavily concentrated, with Medtronic and Cardiac Pacemakers together commanding the largest share of activity across 1,267 patent families in scope. Annual filing volume peaked around 2017 and has eased since, signaling a maturing competitive environment dominated by a small number of established device makers.
Medtronic leads a tightly concentrated field with a clear tier gap
Medtronic holds the top position among all filers, with Cardiac Pacemakers ranking second. Together, the top five filers account for 59% of the combined patent records held by the hundred largest filers, indicating a highly concentrated competitive structure.
The gap between the top two players and the rest of the ranking is substantial: Medtronic and Cardiac Pacemakers each hold notably more patent records than Pacesetter (third), ELA Medical (fourth), and Biotronik (fifth), creating a pronounced two-tier hierarchy.
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 1 | Medtronic Inc. | 829 | |
| 2 | Cardiac Pacemakers Inc. | 686 | |
| 3 | Pacesetter Inc. | 346 | |
| 4 | ELA Medical SA | 291 | |
| 5 | BIOTRONIK SE & CO KG | 250 | |
| 6 | West Affum Holdings DAC | 132 | |
| 7 | Intermedics Inc. | 129 | |
| 8 | Cameron Health Inc. | 109 | |
| 9 | St. Jude Medical AB | 103 | |
| 10 | Koninklijke Philips N.V. | 91 |
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 11 | ZOLL Medical Corporation | 81 | |
| 12 | Physio-Control Corp. | 54 | |
| 13 | Stryker Corporation | 42 | |
| 14 | Element Science Inc. | 39 | |
| 15 | Siemens AG | 38 | |
| 16 | CardioThrive Inc. | 30 | |
| 17 | Nanostim Inc. | 29 | |
| 18 | Telectronics | 28 | |
| 19 | iRhythm Technologies Inc. | 27 | |
| 20 | Purdue Research Foundation | 24 |
The strength of the top two positions suggests that new entrants face a dense prior-art landscape in core electrotherapy and implantable device claims, while smaller specialists — such as West Affum, Cameron Health, and iRhythm Technologies — occupy narrower sub-segments.
Filing counts for 2024–2026 are likely under-represented due to typical patent-publication lag; the apparent decline in those years should not be interpreted as a structural withdrawal by any applicant. Longer-window growth, applicant concentration, and technology-route coverage are therefore more reliable signals than the latest-year bar alone.
Filing volume has eased from its 2017 peak; electrotherapy dominates the technology mix
The annual trend and technology composition charts together reveal a field that built its core IP base earlier in the decade and is now consolidating, while a handful of adjacent technology branches remain comparatively sparse.
Annual filing trend
Activity peaked at 203 filings in 2017 and has trended downward since, with 2024 and 2025 figures almost certainly under-counted due to publication lag. The sustained multi-year decline from 2017 through 2023 is the more reliable signal and is consistent with a maturing, post-peak field.
↗ Hover for values · click a bar to ask EurekaTechnology composition
A61N (Electrotherapy and radiation therapy) is overwhelmingly dominant, reflecting the core pacing and defibrillation IP. A61B (Diagnosis and surgery) is a meaningful secondary branch. All other classes — including G16H (Healthcare informatics), G06F (Digital data processing), and H04B (Transmission) — individually represent a small fraction of total activity, indicating limited patent coverage in software, connectivity, and digital health extensions of the core devices.
↗ Hover for values · click a bar to ask EurekaHighly cited patent families surfaced by the query
Citation-heavy patent families returned by the query. Use this section as citation context, not as a curated list of the most topic-specific patents.
Cardiac stimulator and defibrillator with means fo…
A medical interventional device is structured for implantation in a human patient, to respond to detection of cardiac activity of the patient indicative of cardiac dysrhythmias. The device includes a cardiac therapy system responsive to a detected arrhythmia in either the atrial or ventricular chambers for automatic therapeutic treatment by selective… (excerpt from the patent abstract)
| # | Patent | Citations |
|---|---|---|
| 1 | Combined remodeling control therapy and anti-remod… | 1,667 |
| 2 | Apparatus for monitoring electrical physiologic si… | 1,497 |
| 3 | Interactive programming and diagnostic system for … | 1,095 |
| 4 | System for producing prioritized alarm messages in… | 958 |
| 5 | Method and apparatus for implementing activity sen… | 885 |
| 6 | Implantable capacitive absolute pressure and tempe… | 846 |
| 7 | Rechargeable biomedical battery powered devices wi… | 789 |
| 8 | System for detecting, diagnosing, and treating car… | 760 |
Ranked by total forward citations. Citation counts favour older and broadly cited patent families, and broad or adjacent patents may appear when they match the search scope. Treat this section as citation context, not as a curated list of the most topic-specific patents. Some patent titles may be shown in their original, non-English language where an accurate translation could not be guaranteed.
What the portfolio structure means for R&D investment decisions
The combination of high concentration, a post-peak filing trajectory, and narrow technology diversification shapes where incremental and disruptive R&D investments are most and least defensible.
Post-peak field in decline stage
The lifecycle evidence places this field in Decline, with annual filings easing back from the 2017 peak of 203 filings. Core pacing and defibrillation IP is densely populated, suggesting that incremental improvement claims face significant prior-art pressure. R&D investment is most defensible in adjacent or enabling technologies not yet heavily patented.
Lifecycle: DeclineTwo-tier structure with a wide leader gap
The top five filers hold 59% of the patent records among the hundred largest filers, with Medtronic and Cardiac Pacemakers far ahead of the next tier. This concentration means that freedom-to-operate analysis is essential before entering core device claim areas. Smaller players such as iRhythm Technologies and Element Science signal that sub-segment specialization remains viable.
HHI: HighLimited but academically anchored co-filing activity
Cardiac Pacemakers has co-filed with the Trustees of Columbia University in the City of New York and with the Research Foundation of the State University of New York (four co-filings each), and with Duke University (one co-filing). ST Jude Medical AB has co-filed with Siemens (four co-filings). These academic partnerships suggest that basic sensing and diagnostics research continues to flow from university labs into commercial portfolios, a path worth monitoring for early signals.
Academic linksUS-centric filing with significant European coverage
The United States is the dominant filing jurisdiction, followed by EPO (Europe), China, WIPO (PCT), and Germany. Australia, Canada, and Japan each hold meaningful positions as secondary markets. China’s presence is notable but still well behind the US and EPO, indicating potential gaps in Asian patent protection that competitors could exploit or that entrants might find less encumbered.
Lead office: USGo beyond the landscape: Eureka’s TRIZ Solution agent breaks down an R&D problem and returns patented concept solutions, each with a technical approach and cited patent & literature evidence.
| Applicant | Collaborator | Co-filings |
|---|---|---|
| Cardiac Pacemakers Inc. | Trustees of Columbia University in the City of New York | 4 |
| Cardiac Pacemakers Inc. | Research Foundation of the State University of New York | 4 |
| St. Jude Medical AB | Siemens AG | 4 |
| Cardiac Pacemakers Inc. | Duke University | 1 |
Co-filing pairs, ranked by the number of jointly-filed patent families.
Medtronic and Cardiac Pacemakers lead; Biotronik holds ground while others retreat
The top two players are anchored overwhelmingly in core electrotherapy (A61N1) and diagnostic surgery (A61B5) claims, reflecting deep incumbency in implantable pacing and defibrillation. Momentum trends diverge sharply below the top two.
Medtronic
Medtronic holds 829 patent records, the largest position in the ranking, concentrated in A61N1 (electrotherapy, 826 records) and A61B5 (diagnosis, 207 records), with a smaller presence in A61M5. Recent filing momentum is modestly positive at +6%, suggesting active portfolio maintenance rather than withdrawal. Their breadth across both core device and diagnostic sensing claims makes them the benchmark for freedom-to-operate analysis.
records: 829Biotronik
Biotronik (Biotronik SE & Co. KG) holds 250 patent records, ranking fifth overall, with focus on A61N1 (223 records) and A61B5 (46 records), plus a small G01R31 position reflecting electrical measurement capabilities. Recent momentum is slightly negative at -8%, meaning its relative position is holding better than several mid-tier peers whose filings have dropped sharply. Biotronik represents the strongest non-US challenger in core CRM IP.
records: 250| Applicant | Recent (3 yrs) | Trend |
|---|---|---|
| Medtronic Inc. | 38 | ▲ +6% |
| Cardiac Pacemakers Inc. | 4 | ▲ new entrant |
| Pacesetter Inc. | 8 | ▼ -58% |
| Biotronik SE & Co. KG | 35 | ▼ -8% |
| Koninklijke Philips N.V. | 3 | ▲ new entrant |
| West Affum Holdings Corp. | 7 | ▼ -84% |
Under-served branches in informatics, connectivity, and fluid management
Several IPC classes adjacent to the dominant A61N electrotherapy core carry comparatively low patent counts relative to the overall corpus, representing under-served areas that may offer less encumbered entry points for targeted R&D.
G16H · Healthcare Informatics
With only 105 patent records and a 1% share of the technology composition, healthcare informatics — covering remote monitoring platforms, clinical decision support, and patient data integration for CRM devices — is sparsely covered. As payers and health systems increasingly require outcome analytics alongside devices, this branch has plausible technical value. Entry paths include software-defined remote monitoring, AI-assisted arrhythmia classification, and interoperability standards for implantable device data.
Search this in Eureka →H04B · Transmission (General)
Wireless transmission protocols for implantable and wearable CRM devices account for only 58 patent records and a 1% share. Given the industry shift toward leadless pacemakers, wireless recharging, and secure telemetry, this branch has clear technical relevance. The sparse coverage suggests that novel communication architectures — particularly low-power, body-area-network protocols — may be claimable with targeted investment.
Search this in Eureka →How leading applicants differ across technology routes
Route coverage across the main technology branches in the current evidence set.
| Player | A61N 1 · Electrotherapy & radiation therapy | A61B 5 · Diagnosis & surgery | A61B 7 · Diagnosis & surgery | G16H 40 · Healthcare informatics | A61H 31 · Physical therapy & massage |
|---|---|---|---|---|---|
| Medtronic Inc. | Strong · 826 | Moderate · 207 | Absent | Absent | Absent |
| Cardiac Pacemakers Inc. | Strong · 611 | Moderate · 157 | Emerging · 13 | Absent | Absent |
| ELA Medical SA | Strong · 364 | Emerging · 32 | Absent | Absent | Absent |
| Pacesetter Inc. | Strong · 242 | Emerging · 31 | Absent | Absent | Absent |
| Biotronik SE & Co. KG | Strong · 223 | Moderate · 46 | Absent | Absent | Absent |
| West Affum Holdings Corp. | Strong · 90 | Strong · 65 | Emerging · 4 | Emerging · 4 | Absent |
| Koninklijke Philips N.V. | Strong · 84 | Strong · 56 | Emerging · 13 | Absent | Absent |
Frequently asked questions
The evidence covers 1,267 patent families in scope for this topic.
Medtronic holds the leading position with 829 patent records in the ranking, well ahead of second-ranked Cardiac Pacemakers with 686 patent records.
No. The field is in a Decline lifecycle stage, with annual filings easing back from a peak of 203 in 2017. The most recent years (2024–2026) are likely under-counted due to publication lag, but the multi-year downtrend from 2017 onward is the reliable signal.
A61N (Electrotherapy and radiation therapy) is overwhelmingly dominant. A61B (Diagnosis and surgery) is the second-largest branch, with all other classes representing comparatively minor shares of total activity.
The United States is the lead filing jurisdiction, followed by EPO (Europe), China, WIPO (PCT), and Germany. Australia, Canada, and Japan are significant secondary markets.
Healthcare informatics (G16H) and wireless transmission (H04B) are the sparsest adjacent branches relative to the core electrotherapy domain, each representing roughly 1% of patent-record activity. Digital data processing (G06F) and physical therapy interfaces (A61H) are similarly sparse and may offer less encumbered entry points.
Ready to map your own cardiac rhythm management patent landscape?
Join 18,000+ innovators using PatSnap Eureka to map any technology landscape: search 2B+ patents and papers, surface key assignees, and generate a report like this in minutes.
Disclaimer. This page is generated from PatSnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. PatSnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.